Have a personal or library account? Click to login

References

  1. AAES, T.A.A.o.E.S. Primary hyperaldosteronism (Conn’s syndrome or aldosterone-producing adrenal tumor). Patient Education. 2016.
  2. Agharazii M, Douville P, Grose JH, Lebel M. Captopril suppression versus salt loading in confirming primary aldosteronism. Hypertension 37, 1440-1443, 2001.10.1161/01.HYP.37.6.144011408392
  3. Ahmed AH, Gordon RD, Sukor N, Pimenta E, Stowasser M. Quality of life in patients with bilateral primary aldosteronism before and during treatment with spironolactone and/or amiloride, including a comparison with our previously published results in those with unilateral disease treated surgically. J Clin Endocrinol Metab 96, 2904-2911, 2011.10.1210/jc.2011-013821778218
  4. Al-Salameh A, Cohen R, Desailloud R. Overview of the genetic determinants of primary aldosteronism. Appl Clin Genet 7, 67-79, 2014.10.2147/TACG.S45620401234524817817
  5. Amar L, Lorthioir A, Azizi M, Plouin PF. Progress in primary aldosteronism. Mineralocorticoid antagonist treatment for aldosterone-producing adenoma. Eur J Endocrinol 172, R125-R129, 2015.10.1530/EJE-14-058525315875
  6. Armanini D, Karbowiak I, Goi A, Mantero F, Funder JW. In-vivo metabolites of spironolactone and potassium canrenoate: determination of potential anti-androgenic activity by a mouse kidney cytosol receptor assay. Clin Endocrinol (Oxf) 23, 341-347, 1985.10.1111/j.1365-2265.1985.tb01090.x4064345
  7. Aronova A, Fahey TJ, Zarnegar R Management of hypertension in primary aldosteronism. World J Cardiol 6, 227-233, 2014a.10.4330/wjc.v6.i5.227406212524944753
  8. Aronova A, Gordon BL, Finnerty BM, Zarnegar R, Fahey TJ 3rd. Aldosteronoma resolution score predicts long-term resolution of hypertension. Surgery 156, 1387-1393, 2014b.10.1016/j.surg.2014.08.01925456916
  9. Assalia A, Gagner M. Laparoscopic adrenalectomy. Br J Surg 91, 1259-1274, 2004.10.1002/bjs.473815376201
  10. Bagrodia A, Kopp RP, Mehrazin R, Lee HJ, Liss MA, Jabaji R, Kane CJ, Wake RW, Patterson AL, Wan JY, Derweesh IH. Impact of renal surgery for cortical neoplasms on lipid metabolism. BJU Int 114, 837-843, 2014.10.1111/bju.1274424656182
  11. Bergstrom M, Juhlin C, Bonasera TA, Sundin A, Rastad J, Akerstrom G, Langstrom B. PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate. J Nucl Med 41, 275-282, 2000.
  12. Boland GW, Dwamena BA, Jagtiani Sangwaiya M, Goehler AG, Blake MA, Hahn PF, Scott JA, Kalra MK. Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance. Radiology 259, 117-126, 2011.10.1148/radiol.1110056921330566
  13. Brown NJ. Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens 14, 235-241, 2005.10.1097/01.mnh.0000165889.60254.9815821416
  14. Brown MJ. Primary Aldosteronism: the spectre of cure. Clin Endocrinol (Oxf) 82, 785-788, 2015.10.1111/cen.1279625891888
  15. Brunt LM. Minimal access adrenal surgery. Surg Endosc 20, 351-361, 2006.10.1007/s00464-004-8269-316437282
  16. Brunt LM, Moley JF. Adrenal incidentaloma. World J Surg 25, 905-913, 2001.10.1007/s00268-001-0029-011572032
  17. Burton TJ, Mackenzie IS, Balan K, Koo B, Bird N, Soloviev DV, Azizan EA, Aigbirhio F, Gurnell M, Brown MJ. Evaluation of the sensitivity and specificity of 11C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn’s adenomas. J Clin Endocrinol Metab 97, 100-109, 2012.10.1210/jc.2011-153722112805
  18. Chai YJ, Kwon H, Yu HW, Kim SJ, Choi JY, Lee KE, Youn YK. Systematic review of surgical approaches for adrenal tumors: lateral transperitoneal versus posterior retroperitoneal and laparoscopic versus robotic adrenalectomy. Int J Endocrinol 2014, 918346, 2014.10.1155/2014/918346428139825587275
  19. Chao CT, Wu VC, Kuo CC, Lin YH, Chang CC, Chueh SJ, Wu KD, Pimenta E, Stowasser M. Diagnosis and management of primary aldosteronism: an updated review. Ann Med 45, 375-383, 2013.10.3109/07853890.2013.78523423701121
  20. Chen W, Li F, Chen D, Zhu Y, He C, Du Y, Tan W. Retroperitoneal versus transperitoneal laparoscopic adrenalectomy in adrenal tumor: a meta-analysis. Surg Laparosc Endosc Percutan Tech 23, 121-127, 2013.10.1097/SLE.0b013e3182827b5723579504
  21. Chiang WF, Cheng CJ, Wu ST, Sun GH, Lin MY, Sung CC, Lin SH. Incidence and factors of post-adrenalectomy hyperkalemia in patients with aldosterone producing adenoma. Clin Chim Acta 424, 114-118, 2013.10.1016/j.cca.2013.05.01723727469
  22. Conder G, Rendle J, Kidd S, Misra RR. A-Z of Abdominal Radiology, Cambridge University Press, Cambridge, UK, 28-37, 2009.10.1017/CBO9780511575792
  23. Conn JW. Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 45, 3-17, 1955.
  24. Constantinides VA, Christakis I, Touska P, Palazzo FF. Systematic review and meta-analysis of retroperitoneoscopic versus laparoscopic adrenalectomy. Br J Surg 99, 1639-1648, 2012.10.1002/bjs.8921
  25. Ctvrtlik F, Koranda P, Tichy T. Adrenal disease: a clinical update and overview of imaging. A review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 158, 23-34, 2014.10.5507/bp.2014.010
  26. Dunnick NR, Korobkin M. Imaging of adrenal incidentalomas: current status. AJR Am J Roentgenol 179, 559-568, 2002.10.2214/ajr.179.3.1790559
  27. Dupont A. Disappearance of spironolactone-induced gynaecomastia during treatment with potassium canrenoate. Lancet 2, 731, 1985.10.1016/S0140-6736(85)92975-7
  28. Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 85 1863-1867, 2000.10.1210/jcem.85.5.659610843166
  29. Fischer E, Hanslik G, Pallauf A, Degenhart C, Linsenmaier U, Beuschlein F, Bidlingmaier M, Mussack T, Ladurner R, Hallfeldt K, Quinkler M, Reincke M. Prolonged zona glomerulosa insufficiency causing hyperkalemia in primary aldosteronism after adrenalectomy. J Clin Endocrinol Metab 97, 3965-3973, 2012.10.1210/jc.2012-223422893716
  30. Fischer E, Reuschl S, Quinkler M, Rump LC, Hahner S, Bidlingmaier M, Reincke M; Participants of the German Conn’s Registry-Else Kroner-Fresenius-Hyperaldosteronism Registry. Assay characteristics influence the aldosterone to renin ratio as a screening tool for primary aldosteronism: results of the German Conn’s registry. Horm Metab Res 45, 526-531, 2013.10.1055/s-0033-134344823613013
  31. Fleming T, ed. 2005 Red Book: Pharmacy’s Fundamental Reference. Montvale NJ: Thomson PDR, 2005.
  32. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr, Montori VM; Endocrine Society. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93, 3266-3281, 2008.10.1210/jc.2008-010418552288
  33. Geller DS, Zhang J, Wisgerhof MV, Shackleton C, Kashgarian M, Lifton RP. A novel form of human mendelian hypertension featuring nonglucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 93, 3117-3123, 2008.10.1210/jc.2008-0594251508318505761
  34. Giacchetti G, Ronconi V, Lucarelli G, Boscaro M, Mantero F. Analysis of screening and confirmatory tests in the diagnosis of primary aldosteronism: need for a standardized protocol. J Hypertens 24, 737-745, 2006.10.1097/01.hjh.0000217857.20241.0f16531803
  35. Gordon R. Mineralocorticoid hypertension. Lancet 344, 240-243, 1994.10.1016/S0140-6736(94)93003-1
  36. Gordon RD, Stowasser M, TunnyTJ, Klemm SA, Rutherford JC. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 21, 315-318, 1994.10.1111/j.1440-1681.1994.tb02519.x
  37. Gordon R. Primary aldosteronism. J Endocrinol Invest 18, 495-511, 1995.10.1007/BF03349761
  38. Gordon RD. Diagnostic investigations in primary aldosteronism. In: Zanchetti A (ed.), Clinical Medicine Series on Hypertension. Maidenhead: McGraw-Hill International (UK) Ltd; pp. 101-114, 2001.
  39. Hiramatsu K, Yamada T, Yukimura Y, Komiya I, Ichikawa K, Ishihara M, Nagata H, Izumiyama T. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity: results in hypertensive patients. Arch Intern Med 141, 1589-1593, 1981.10.1001/archinte.141.12.1589
  40. Hofer M. Kidneys and Adrenal Glands. Ultrasound Teaching Manual Hofer, Matthias, Thieme, 37-50, 1999.
  41. Hood S, Cannon J, Foo R, Brown M. Prevalence of primary hyperaldosteronism assessed by aldosterone/renin ratio and spironolactone testing. Clin Med (Lond) 5, 55-60, 2005.10.7861/clinmedicine.5-1-55
  42. Iacobone M, Citton M, Viel G, Rossi GP, Nitti D. Approach to the surgical management of primary aldosteronism. Gland Surg 4, 69-81, 2015.
  43. Ilias I, Sahdev A, Reznek RH, Grossman AB, Pacak K. The optimal imaging of adrenal tumours: a comparison of different methods. Endocr Relat Cancer 14, 587-599, 2007.10.1677/ERC-07-0045
  44. Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF, Corvol P, Menard J. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 60, 820-825, 1987.10.1016/0002-9149(87)91030-7
  45. Kaga M, Utsumi T, Tanaka T, Kono T, Nagano H, Kawamura K, Kamiya N, Imamoto T, Nihei N, Naya Y, Suzuki H, Ichikawa T. Risk of new-onset dyslipidemia after laparoscopic adrenalectomy in patients with primary aldosteronism. World J Surg 39, 2935-2940, 2015.10.1007/s00268-015-3197-z26296835
  46. Kahn SL, Angle JF. Adrenal vein sampling. Tech Vasc Interv Radiol 13, 110-125, 2010.10.1053/j.tvir.2010.02.00620540920
  47. Kem DC, Weinberger MH, Mayes DM, Nugent CA. Saline suppression of plasma aldosterone in hypertension. Arch Intern Med 128, 380-386, 1971.10.1001/archinte.128.3.380
  48. Kline GA. Primary Aldosteronism: unnecessary complexity in definition and diagnosis as a barrier to wider clinical care. Clin Endocrinol (Oxf) 82, 779-784, 2015.10.1111/cen.1279825891981
  49. Kucharz EJ. [Michal Litynski--a forgotten author of the first description on primary hyperaldosteronism]. Pol Arch Med Wewn 117, 57-58, 2007.10.20452/pamw.79
  50. Lafferty AR, Torpy DJ, Stowasser M, Taymans SE, Lin JP, Huggard P, Gordon RD, Stratakis CA. A novel genetic locus for low renin hypertension: familial hyperaldosteronism type II maps to chromosome 7 (7p22). J Med Genet 37, 831-835, 2000.10.1136/jmg.37.11.831173446811073536
  51. Lee J, El-Tamer M, Schifftner T, Turrentine FE, Henderson WG, Khuri S, Hanks JB, Inabnet WB 3rd. Open and laparoscopic adrenalectomy: analysis of the National Surgical Quality Improvement Program. J Am Coll Surg 206, 953-961, 2008.10.1016/j.jamcollsurg.2008.01.01818471733
  52. Letavernier E, Peyrard S, Amar L, Zinzindohoue F, Fiquet B, Plouin PF. Blood pressure outcome of adrenalectomy in patients with primary hyperaldosteronism with or without unilateral adenoma. J Hypertens 26, 1816-1823, 2008.10.1097/HJH.0b013e3283060f0c18698217
  53. Litchfield WR, Anderson BF, Weiss RJ, Lifton RP, Dluhy RG. Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension 31, 445-450, 1998.10.1161/01.HYP.31.1.445
  54. Mantero F, Fallo F, Opocher G, Armanini D, Boscaro M, Scaroni C. Effect of angiotensin II and converting enzyme inhibitor (captopril) on blood pressure, plasma renin activity and aldosterone in primary aldosteronism. Clin Sci (Lond) 61, 289s-293s, 1981.10.1042/cs061289s7032817
  55. Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, Giovagnetti M, Opocher G, Angeli A. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 85, 637-644, 2000.10.1210/jcem.85.2.637210690869
  56. Mattsson C, Young WF. Primary aldosteronism: diagnostic and treatment strategies. Nat Clin Pract Nephrol 2, 198-208, 2006.10.1038/ncpneph015116932426
  57. McCurley A, Pires PW, Bender SB, Aronovitz M, Zhao MJ, Metzger D, Chambon P, Hill MA, Dorrance AM, Mendelsohn ME, Jaffe IZ. Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors. Nat Med 18, 1429-1433, 2012.10.1038/nm.2891349108522922412
  58. McKenna TJ, Sequeira SJ, Heffernan A, Chambers J, Cunningham S. Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary hyperaldosteronism. J Clin Endocrinol Metab 73, 952-957, 1991.10.1210/jcem-73-5-9521939533
  59. Melby JC, Spark RF, Dale SL, Egdahl RH, Kahn PC. Diagnosis and localization of aldosterone-producing adenomas by adrenal-vein catheterization. N Engl J Med 277, 1050-1056, 1967.10.1056/NEJM1967111627720026059584
  60. Mengozzi G, Rossato D, Bertello C, Garrone C, Milan A, Pagni R, Veglio F, Mulatero P. Rapid cortisol assay during adrenal vein sampling in patients with primary aldosteronism. Clin Chem 53, 1968-1971, 2007.10.1373/clinchem.2007.09208017901112
  61. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 45, 1243-1248, 2005.10.1016/j.jacc.2005.01.01515837256
  62. Monticone S, Hattangady NG, Penton D, Isales CM, Edwards MA, Williams TA, Sterner C, Warth R, Mulatero P, Rainey WE. A novel Y152C KCNJ5 mutation responsible for familial hyperaldosteronism type III. J Clin Endocrinol Metab 98, E1861-E1865, 2013.10.1210/jc.2013-2428381626524037882
  63. Moraitis A, Stratakis C. Adrenocortical causes of hypertension. Int J Hypertens 2011, 624691, 2011.10.4061/2011/624691305702921423682
  64. Mulatero P, Rabbia F, Milan A, Paglieri C, Morello F, Chiandussi L, Veglio F. Drug effects on aldosterone/plasma renin activity ratio in primary aldosteronism. Hypertension 40, 897-902, 2002.10.1161/01.HYP.0000038478.59760.4112468576
  65. Mulatero P, Stowasser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, Veglio F, Young WF Jr. Increased diagnosis of primary aldosteronism, including surgically correctable forms in centers from five continents. J Clin Endocrinol Metab 89, 1045-1050, 2004.10.1210/jc.2003-03133715001583
  66. Mulatero P, Monticone S, Bertello C, Viola A, Tizzani D, Iannaccone A, Crudo V, Burrello J, Milan A, Rabbia F, Veglio F. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. J Clin Endocrinol Metab 98, 4826-4833, 2013.10.1210/jc.2013-280524057288
  67. Papierska L, Cichocki A, Sankowski AJ, Cwikla JB. Adrenal incidentaloma imaging - the first steps in therapeutic management. Pol J Radiol 78, 47-55, 2013.10.12659/PJR.889541390850724505223
  68. Piecha G, Adamczak M, Ritz E. Dyslipidemia in chronic kidney disease. Pol Arch Med Wewn 119, 487-492, 2009.10.20452/pamw.745
  69. Powlson AS, Gurnell M, Brown MJ. Nuclear imaging in the diagnosis of primary aldosteronism. Curr Opin Endocrinol Diabetes Obes 22, 150-156, 2015.10.1097/MED.0000000000000148
  70. Probst KA, Ohlmann CH, Saar M, Siemer S, Stoeckle M, Janssen M. Robot-assisted vs open adrenalectomy: evaluation of cost-effectiveness and peri-operative outcome. BJU Int 118, 952-957, 2016.10.1111/bju.13529
  71. Ramsay LE, Hettiarachchi J, Fraser R, Morton JJ. Amiloride, spironolactone, and potassium chloride in thiazidetreated hypertensive patents. Clin Pharmacol Ther 27, 533-543, 1980.10.1038/clpt.1980.75
  72. Reincke M, Rump LC, Quinkler M, Hahner S, Diederich S, Lorenz R, Seufert J, Schirpenbach C, Beuschlein F, Bidlingmaier M, Meisinger C, Holle R, Endres S; Participants of German Conn’s Registry. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. J Clin Endocrinol Metab 94, 869-875, 2009.10.1210/jc.2008-1851
  73. Rossi E, Regolisti G, Negro A, Sani C, Davoli S, Perazzoli F. High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 15, 896-902, 2002.10.1016/S0895-7061(02)02969-2
  74. Rossi GP, Bernini G, Caliumi C, Desideri G, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F; PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 48, 2293-2300, 2006a.10.1016/j.jacc.2006.07.05917161262
  75. Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, Matterello MJ, Montemurro D, Palumbo G, Rizzoni D, Rossi E, Pessina AC, Mantero F; PAPY Study Participants. Renal damage in primary aldosteronism results of the PAPY study. Hypertension 48, 232-238, 2006b.10.1161/01.HYP.0000230444.01215.6a16801482
  76. Rossi GP, Ganzaroli C, Miotto D, De Toni R, Palumbo G, Feltrin GP, Mantero F, Pessina AC. Dynamic testing with high-dose adrenocorticotrophic hormone does not improve lateralization of aldosterone oversecretion in primary aldosteronism patients. J Hypertens 24, 371-379, 2006c.10.1097/01.hjh.0000202818.10459.9616508586
  77. Rossi GP, Belfiore A, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Palumbo G, Rizzoni D, Rossi E, Agabiti-Rosei E, Pessina AC, Mantero F; Primary Aldosteronism Prevalence in Italy Study Investigators. Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension 50, 424-443, 2007.10.1161/HYPERTENSIONAHA.107.09182717592070
  78. Rossi GP, Pitter G, Bernante P, Motta R, Feltrin G, Miotto D. Adrenal vein sampling for primary aldosteronism: the assessment of selectivity and lateralization of aldosterone excess baseline and after adrenocorticotropic hormone (ACTH) stimulation. J Hypertens 26, 989-997, 2008.10.1097/HJH.0b013e3282f9e66a18398342
  79. Schirpenbach C, Seiler L, Maser-Gluth C, Rudiger F, Nickel C, Beuschlein F, Reincke M. Confirmatory testing in normokalaemic primary aldosteronism: the value of saline infusion test and urinary aldosterone metabolites. Eur J Endocrinol 154, 865-873, 2006.10.1530/eje.1.0216416728547
  80. Schirpenbach C, Reincke M. Primary aldosteronism: current knowledge and controversies in Conn’s syndrome. Nat Clin Pract Endocrinol Metab 3, 220-227, 2007.10.1038/ncpendmet043017315030
  81. Schwartz GL, Turner ST. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem 51, 386-394, 2005.10.1373/clinchem.2004.04178015681560
  82. Shen WT, Lim RC, Siperstein AE, Clark OH, Schecter WP, Hunt TK, Horn JK, Duh QY. Laparoscopic vs open adrenalectomy for the treatment of primary hyperaldosteronism. Arch Surg 134, 628-632, 1999.10.1001/archsurg.134.6.62810367872
  83. Sica DA. Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 10, 23-29, 2005.10.1007/s10741-005-2345-115947888
  84. So A, Duffy DL, Gordon RD, Jeske YW, Lin-Su K, New MI, Stowasser M. Familial hyperaldosteronism type II is linked to the chromosome 7p22 region but also shows predicted heterogeneity. J Hypertens 23, 1477-1484, 2005.10.1097/01.hjh.0000174299.66369.2616003173
  85. Spyridonidis TJ, Apostolopoulos DJ. Is there a role for Nuclear Medicine in diagnosis and management of patients with primary aldosteronism? Hell J Nucl Med 16, 134-139, 2013.
  86. Steichen O, Lorthioir A, Zinzindohoue F, Plouin PF, Amar L. Outcomes of drug-based and surgical treatments for primary aldosteronism. Adv Chronic Kidney Dis 22, 196-203, 2015.10.1053/j.ackd.2014.10.00325908468
  87. Stowasser M, Gordon RD, Gunasekera TG, Cowley DC, Ward G, Archibald C, Smithers BM. High rate of detection of primary aldosteronism, including surgically treatable forms, after a “non-selective” screening of hypertensive patients. J Hypertens 21, 2149-2157, 2003.10.1097/00004872-200311000-0002514597859
  88. Stowasser M, Gordon RD. Primary aldosteronism--careful investigation is essential and rewarding. Mol Cell Endocrinol 217, 33-39, 2004.10.1016/j.mce.2003.10.00615134798
  89. Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D, Marwick TH. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab 90, 5070-5076, 2005.10.1210/jc.2005-068115941863
  90. Stowasser M, Ahmed A, Pimenta E, Taylor PJ, Gordon RD. Factors affecting the aldosterone/renin ratio. Horm Metab Res 44, 170-176, 2012.10.1055/s-0031-129546022147655
  91. Szolar DH, Korobkin M, Reittner P, Berghold A, Bauernhofer T, Trummer H, Schoellnast H, Preidler KW, Samonigg H. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT. Radiology 234, 479-485, 2005.10.1148/radiol.234203187615671003
  92. TAIPAI Study Group, Wu VC, Chueh SC, Chang HW, Lin LY, Liu KL, Lin YH, Ho YL, Lin WC, Wang SM, Huang KH, Hung KY, Kao TW, Lin SL, Yen RF, Chen YM, Hsieh BS, Wu KD. Association of kidney function with residual hypertension after treatment of aldosterone-producing adenoma. Am J Kidney Dis 54, 665-673, 2009.10.1053/j.ajkd.2009.06.01419628318
  93. Takeda M, Go H, Imai T, Nishiyama T, Morishita H. Laparoscopic adrenalectomy for primary aldosteronism: report of initial ten cases. Surgery 115, 621-625, 1994.
  94. Tang K, Li H, Xia D, Yu G, Guo X, Guan W, Xu H, Ye Z. Robot-assisted versus laparoscopic adrenalectomy: a systematic review and meta-analysis. J Laparoendosc Adv Surg Tech A 25, 187-195, 2015.10.1089/lap.2014.043125763475
  95. Thompson GB, Young WF Jr. Adrenal incidentaloma. Curr Opin Oncol 15, 84-90, 2003.10.1097/00001622-200301000-0001312490767
  96. Tomaschitz A, Pilz S. Aldosterone to renin ratio--a reliable screening tool for primary aldosteronism? Horm Metab Res 42, 382-391, 2010.10.1055/s-0030-124832620225167
  97. Utsumi T, Kawamura K, Imamoto T, Nagano H, Tanaka T, Kamiya N, Nihei N, Naya Y, Suzuki H, Ichikawa T. Preoperative masked renal damage in Japanese patients with primary aldosteronism: identification of predictors for chronic kidney disease manifested after adrenalectomy. Int J Urol 20, 685-691, 2013.10.1111/iju.1202923190329
  98. Vaziri N. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 290, F262-F272, 2006.10.1152/ajprenal.00099.200516403839
  99. Walz MK, Alesina PF, Wenger FA, Deligiannis A, Szuczik E, Petersenn S, Ommer A, Groeben H, Peitgen K, Janssen OE, Philipp T, Neumann HP, Schmid KW, Mann K. Posterior retroperitoneoscopic adrenalectomy--results of 560 procedures in 520 patients. Surgery 140, 943-950, 2006.10.1016/j.surg.2006.07.03917188142
  100. Weiner ID. Endocrine and hypertensive disorders of potassium regulation: primary aldosteronism. Semin Nephrol 33, 265-276, 2013.10.1016/j.semnephrol.2013.04.007374839023953804
  101. White ML, Gauger PG, Doherty GM, Cho KJ, Thompson NW, Hammer GD, Miller BS. The role of radiologic studies in the evaluation and management of primary hyperaldosteronism. Surgery 144, 926-933, 2008.10.1016/j.surg.2008.07.02519040999
  102. Worth PJ, Kunio NR, Siegfried I, Sheppard BC, Gilbert EW. Characteristics predicting clinical improvement and cure following laparoscopic adrenalectomy for primary aldosteronism in a large cohort. Am J Surg 210, 702-709, 2015.10.1016/j.amjsurg.2015.05.03326323999
  103. Wu VC, Yang SY, Lin JW, Cheng BW, Kuo CC, Tsai CT, Chu TS, Huang KH, Wang SM, Lin YH, Chiang CK, Chang HW, Lin CY, Lin LY, Chiu JS, Hu FC, Chueh SC, Ho YL, Liu KL, Lin SL, Yen RF, Wu KD; TAIPAI Study Group. Kidney impairment in primary aldosteronism. Clin Chim Acta 412, 1319-1325, 2011.10.1016/j.cca.2011.02.01821345337
  104. Young WF Jr. Primary aldosteronism: management issues. Ann N Y Acad Sci 970, 61-76, 2002.10.1111/j.1749-6632.2002.tb04413.x12381542
  105. Young WF Jr. Minireview: primary aldosteronism--changing concepts in diagnosis and treatment. Endocrinology 144, 2208-2213, 2003a.10.1210/en.2003-027912746276
  106. Young WF Jr. Adrenalectomy for primary aldosteronism; authors’ reply. Ann Intern Med 138, 157-159, 2003b.10.7326/0003-4819-138-2-200301210-0002312529104
  107. Young WF, Stanson AW, Thompson GB, Grant CS, Farley DR, van Heerden JA. Role for adrenal venous sampling in primary aldosteronism. Surgery 136, 1227-1235, 2004.10.1016/j.surg.2004.06.05115657580
  108. Young WF Jr. Clinical practice. The incidentally discovered adrenal mass. N Engl J Med 356, 601-610, 2007.10.1056/NEJMcp06547017287480
  109. Young WF, Stanson AW. What are the keys to successful adrenal venous sampling (AVS) in patients with primary aldosteronism? Clin Endocrinol (Oxf) 70, 14-17, 2009.10.1111/j.1365-2265.2008.03450.x19128364
  110. Zarnegar R, Young WF Jr, Lee J, Sweet MP, Kebebew E, Farley DR, Thompson GB, Grant CS, Clark OH, Duh QY. The aldosteronoma resolution score: predicting complete resolution of hypertension after adrenalectomy for aldosteronoma. Ann Surg 247, 511-518, 2008.10.1097/SLA.0b013e318165c07518376197
DOI: https://doi.org/10.2478/enr-2018-0005 | Journal eISSN: 1336-0329 | Journal ISSN: 1210-0668
Language: English
Page range: 27 - 40
Published on: Feb 16, 2018
Published by: Slovak Academy of Sciences, Mathematical Institute
In partnership with: Paradigm Publishing Services
Publication frequency: 1 times per year

© 2018 Frederick-Anthony Farrugia, Nicolaos Zavras, Georgios Martikos, Panagiotis Tzanetis, Anestis Charalampopoulos, Evangelos P. Misiakos, Dimitrios Sotiropoulos, Nikolaos Koliakos, published by Slovak Academy of Sciences, Mathematical Institute
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.